KR100671367B1 - 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 - Google Patents

미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 Download PDF

Info

Publication number
KR100671367B1
KR100671367B1 KR1020047005588A KR20047005588A KR100671367B1 KR 100671367 B1 KR100671367 B1 KR 100671367B1 KR 1020047005588 A KR1020047005588 A KR 1020047005588A KR 20047005588 A KR20047005588 A KR 20047005588A KR 100671367 B1 KR100671367 B1 KR 100671367B1
Authority
KR
South Korea
Prior art keywords
solid dosage
mycophenolate
mycophenolic acid
tablets
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020047005588A
Other languages
English (en)
Korean (ko)
Other versions
KR20050037409A (ko
Inventor
위르겐 데데릭스
토마스 리가시
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100671367(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20050037409A publication Critical patent/KR20050037409A/ko
Application granted granted Critical
Publication of KR100671367B1 publication Critical patent/KR100671367B1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020047005588A 2001-10-17 2002-10-16 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물 Ceased KR100671367B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0124953.1 2001-10-17
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (2)

Publication Number Publication Date
KR20050037409A KR20050037409A (ko) 2005-04-21
KR100671367B1 true KR100671367B1 (ko) 2007-01-19

Family

ID=9924043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047005588A Ceased KR100671367B1 (ko) 2001-10-17 2002-10-16 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물

Country Status (31)

Country Link
US (3) US20050013859A1 (https=)
EP (1) EP1438040B2 (https=)
JP (2) JP2005508959A (https=)
KR (1) KR100671367B1 (https=)
CN (1) CN1310640C (https=)
AR (2) AR036813A1 (https=)
AT (1) ATE374023T1 (https=)
AU (1) AU2002338897B2 (https=)
BR (1) BR0213355A (https=)
CA (1) CA2460574A1 (https=)
CO (1) CO5390076A1 (https=)
CY (1) CY1107841T1 (https=)
DE (1) DE60222687T3 (https=)
DK (1) DK1438040T4 (https=)
EC (2) ECSP024341A (https=)
ES (1) ES2292819T5 (https=)
GB (1) GB0124953D0 (https=)
HU (1) HU231114B1 (https=)
IL (2) IL160968A0 (https=)
MX (1) MXPA04003636A (https=)
MY (1) MY139206A (https=)
NO (1) NO341804B1 (https=)
NZ (1) NZ532280A (https=)
PE (1) PE20030476A1 (https=)
PL (2) PL415001A1 (https=)
PT (1) PT1438040E (https=)
RU (2) RU2338528C2 (https=)
SI (1) SI1438040T2 (https=)
TW (1) TWI333861B (https=)
WO (1) WO2003032978A1 (https=)
ZA (1) ZA200401977B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US20060069150A1 (en) * 2004-07-20 2006-03-30 Sandor Molnar Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
US8597679B2 (en) 2005-12-21 2013-12-03 Basf Se Fine-particle crosslinked polyvinylpyrrolidone as tablet disintegrant
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
CN102083410B (zh) 2007-06-06 2013-04-17 巴斯夫欧洲公司 用于制备迅速崩解的片剂的药物制剂
KR20160083132A (ko) 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
KR20100126465A (ko) * 2008-03-05 2010-12-01 파나세아 바이오테크 리미티드 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
WO2018170022A2 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
AU2019286326A1 (en) * 2018-06-14 2020-12-10 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
EP4248958A3 (en) * 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4346790A4 (en) * 2021-05-26 2025-04-16 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
EP0670724A1 (en) * 1992-11-24 1995-09-13 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
CA2156726C (en) * 1993-02-26 2000-10-17 Paula Denise Davis Bisacodyl dosage form
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CZ301771B6 (cs) * 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
EP0724441A1 (en) * 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
JP2002544167A (ja) * 1999-05-10 2002-12-24 ノバルティス アクチエンゲゼルシャフト 有機化合物
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
WO2001064931A1 (en) * 2000-02-29 2001-09-07 Biocon India Limited Manufacture and purification of mycophenolic acid
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MXPA04003636A (es) 2004-07-27
NO20041785L (no) 2004-05-03
TWI333861B (en) 2010-12-01
RU2007130786A (ru) 2009-02-20
ATE374023T1 (de) 2007-10-15
US20100210717A1 (en) 2010-08-19
DK1438040T4 (da) 2020-01-27
CN1564684A (zh) 2005-01-12
EP1438040A1 (en) 2004-07-21
GB0124953D0 (en) 2001-12-05
RU2338528C2 (ru) 2008-11-20
ZA200401977B (en) 2006-05-31
CY1107841T1 (el) 2013-06-19
DK1438040T3 (da) 2008-02-04
AR036813A1 (es) 2004-10-06
CN1310640C (zh) 2007-04-18
HK1067861A1 (en) 2005-04-22
RU2381026C2 (ru) 2010-02-10
SI1438040T2 (sl) 2020-02-28
BR0213355A (pt) 2006-05-23
PL234541B1 (pl) 2020-03-31
AU2002338897B2 (en) 2006-10-19
ES2292819T3 (es) 2008-03-16
ECSP024341A (es) 2003-12-01
DE60222687T2 (de) 2008-07-17
ECSP024342A (es) 2003-03-10
MY139206A (en) 2009-08-28
HUP0600451A2 (en) 2006-09-28
IL160968A (en) 2016-04-21
PT1438040E (pt) 2008-01-02
PL415001A1 (pl) 2016-02-29
JP2005508959A (ja) 2005-04-07
IL160968A0 (en) 2004-08-31
PL367738A1 (en) 2005-03-07
US20050013859A1 (en) 2005-01-20
NZ532280A (en) 2007-05-31
DE60222687T3 (de) 2020-03-05
DE60222687D1 (de) 2007-11-08
KR20050037409A (ko) 2005-04-21
ES2292819T5 (es) 2020-05-29
RU2004115332A (ru) 2005-04-20
NO341804B1 (no) 2018-01-22
EP1438040B1 (en) 2007-09-26
US20120237601A1 (en) 2012-09-20
SI1438040T1 (sl) 2008-04-30
CO5390076A1 (es) 2004-04-30
PE20030476A1 (es) 2003-07-30
WO2003032978A1 (en) 2003-04-24
AR085778A2 (es) 2013-10-30
JP2009137996A (ja) 2009-06-25
HU231114B1 (hu) 2020-09-28
CA2460574A1 (en) 2003-04-24
EP1438040B2 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
KR100671367B1 (ko) 미코페놀산 또는 미코페놀레이트 염을 포함하는 제약조성물
AU2002338897A1 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
US7727553B2 (en) Oral preparations with favorable disintegration characteristics
EP3103448B1 (en) Pharmaceutical compositions comprising an s1p modulator
US20080206322A1 (en) Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
CA2954474A1 (en) Capsule dosage form of metoprolol succinate
US10835497B2 (en) Rivastigmine-containing sustained-release pharmaceutical composition
US20240315978A1 (en) Pharmaceutical compositions comprising acalabrutinib
SK50222004A3 (sk) Kompozície matrice s modifikovaným uvoľňovaním, s dlhodobým účinkom
HK1067861B (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
WO2013054178A9 (en) Extended release pharmaceutical compositions containing carbamazepine
US20070232697A1 (en) Method for preparing free base compositions and formulations thereof
HK1228298B (en) Pharmaceutical compositions comprising an s1p modulator

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040416

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040728

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060327

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20061020

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070112

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100111

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101222

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111221

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121226

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20131219

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20131219

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20141231

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20141231

Start annual number: 9

End annual number: 9

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20150327

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20070112

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20150327

Decision date: 20170119

Appeal identifier: 2015100001592

FPAY Annual fee payment

Payment date: 20151217

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151217

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170102

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170102

Start annual number: 11

End annual number: 11

J301 Trial decision

Free format text: TRIAL NUMBER: 2015100001592; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20170119

PJ1301 Trial decision

Patent event code: PJ13011S05D

Patent event date: 20170119

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20150327

Decision date: 20170119

Appeal identifier: 2015100001592

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2017200001175; INVALIDATION

PJ2001 Appeal

Patent event date: 20170119

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Appeal kind category: Invalidation

Decision date: 20171222

Appeal identifier: 2017200001175

Request date: 20170217

FPAY Annual fee payment

Payment date: 20180103

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180103

Start annual number: 12

End annual number: 12

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2018300010282; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

PJ2002 Appeal before the supreme court

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event date: 20170119

Patent event code: PJ20021S05I

Request date: 20180131

Appeal identifier: 2018300010282

Appeal kind category: Invalidation

Decision date: 20191031

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20190103

Start annual number: 13

End annual number: 13

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2017200001175; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20170217

Effective date: 20171222

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2018300010282; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20180131

Effective date: 20191031

PJ1302 Judgment (patent court)

Patent event date: 20191108

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20170217

Decision date: 20171222

Appeal identifier: 2017200001175

Appeal kind category: Invalidation

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20191108

Patent event code: PJ13031S01D

Decision date: 20191031

Appeal kind category: Invalidation

Request date: 20180131

Appeal identifier: 2018300010282

PJ2201 Remand (intellectual property tribunal)

Patent event code: PJ22012S01I

Comment text: Written Judgment (Patent Court)

Patent event date: 20191108

Request date: 20191108

Appeal kind category: Invalidation

Appeal identifier: 2019130000159

Decision date: 20191121

J301 Trial decision

Free format text: TRIAL NUMBER: 2019130000159; TRIAL DECISION FOR INVALIDATION REQUESTED 20191108

Effective date: 20191121

PJ1301 Trial decision

Patent event code: PJ13011S09D

Patent event date: 20191121

Comment text: Trial Decision on Final Judgment on Revocation

Appeal kind category: Invalidation

Request date: 20191108

Decision date: 20191121

Appeal identifier: 2019130000159

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20200103

Start annual number: 14

End annual number: 14

PC2102 Extinguishment

Termination category: Others

Termination date: 20200304

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20200312